Jan. 21, 2021: Dyad-level interventions in serodiscordant relationships; using social media to improve PrEP uptake; HCV prevalence among MSM; the irrelevance of doxycycline prophylaxis against mycoplasma genitalium.
Participants on the combination were almost six times more likely to have meth-negative urine samples after six weeks than those on the placebo. They also reported a slight reduction in cravings.
Jan. 14, 2021: Interpersonal violence history and adverse HIV outcomes; the incidence and severity of breast cancer; the effect of menopause on integrase-associated weight gain; two-drug therapy for HIV treatment-experienced people.
“ARCA started because there was a heartbreaking need for new drugs to treat HIV,” says Melanie Thompson, M.D. “The landscape for HIV research has indeed changed, largely as a result of our successes.”
Jan. 7, 2021: HIV status and COVID-19 disease severity; associations between tobacco smoking, cancer incidence, viral load, and CD4 count; immune recovery on integrase inhibitors; using smart pill bottles to boost adherence.
A new expert consensus statement explores how providers can give birthing parents who are living with HIV the information they need to decide for themselves.
Dec. 28, 2020: The power of clinic-pharmacy collaborations; overcoming COVID-19-induced barriers to HIV care; urine testing as a PrEP adherence tool; using incarceration history in PrEP Rx assessments.
Dec. 17, 2020: HIV-related mortality in the U.S.; trends in extensive multidrug resistance; 96-week fostemsavir data; statins for microbial cancer prevention.
Self-Swabbing Is an Affirming and Effective Cervical-Cancer Screening Tool for Transmasculine People
Transmasculine people face an array of barriers when understanding their HPV risk and accessing cervical-cancer screenings.
Dec. 10, 2020: Where the Ending the HIV Epidemic plan falls short; housing instability and HIV care incentives; financial wellbeing vs. health care access; San Diego's complex webs of HIV transmission.